Development of a core outcome set for myelodysplastic syndromes – a Delphi study from the EUMDS Registry Group

Treatment options for myelodysplastic syndromes (MDS) vary widely, depending on the natural disease course and patient‐related factors. Comparison of treatment effectiveness is challenging as different endpoints have been included in clinical trials and outcome reporting. Our goal was to develop the...

Descripción completa

Detalles Bibliográficos
Autores principales: Rochau, Ursula, Stojkov, Igor, Conrads‐Frank, Annette, Borba, Helena H., Koinig, Karin A., Arvandi, Marjan, van Marrewijk, Corine, Garelius, Hege, Germing, Ulrich, Symeonidis, Argiris, Sanz, Guillermo F., Fenaux, Pierre, de Witte, Theo, Efficace, Fabio, Siebert, Uwe, Stauder, Reinhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematological Malignancy ‐ Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221029/
https://www.ncbi.nlm.nih.gov/pubmed/32410281
http://dx.doi.org/10.1111/bjh.16654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221029/
https://www.ncbi.nlm.nih.gov/pubmed/32410281
http://dx.doi.org/10.1111/bjh.16654

Ejemplares similares